metformin has been researched along with Choroid Neovascularization in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ying, Y | 1 |
| Ueta, T | 1 |
| Jiang, S | 1 |
| Lin, H | 1 |
| Wang, Y | 1 |
| Vavvas, D | 1 |
| Wen, R | 1 |
| Chen, YG | 1 |
| Luo, Z | 1 |
1 other study available for metformin and Choroid Neovascularization
| Article | Year |
|---|---|
Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.
Topics: Activin Receptors, Type II; Adenylate Kinase; Angiogenesis Inhibitors; Animals; Choroidal Neovascula | 2017 |